185 related articles for article (PubMed ID: 37157005)
21. Case report:
Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
[TBL] [Abstract][Full Text] [Related]
22. Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil.
Queiroz MM; Sacardo KP; Ribeiro MF; Gadotti LL; Saddi R; Oliveira LJC; Linck RDM; Cruz MRS; Barroso-Sousa R; Sahade M; Correa TS; Mano MS; Suzuki DA; Shimada AK; Katz A
Cancer Treat Res Commun; 2023; 35():100683. PubMed ID: 36716534
[TBL] [Abstract][Full Text] [Related]
23. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
24. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I
Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599
[TBL] [Abstract][Full Text] [Related]
25. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
[TBL] [Abstract][Full Text] [Related]
26. Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.
Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38703287
[TBL] [Abstract][Full Text] [Related]
27. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.
Low JL; Lim E; Bharwani L; Wong A; Wong K; Ow S; Lim SE; Lee M; Choo J; Lim J; Chan G; Walsh RJ; Muthu V; Ngoi N; Chong W; Tan SH; Lee SC
Ther Adv Med Oncol; 2022; 14():17588359221139678. PubMed ID: 36570409
[TBL] [Abstract][Full Text] [Related]
28. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
[TBL] [Abstract][Full Text] [Related]
29. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
30. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
Al-Rashdan A; Quirk S; Roumeliotis M; Abedin T; Amaro CP; Barbera L; Lupichuk S; Cao JQ
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):399-408. PubMed ID: 35870712
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real-world experience.
Peng TR; Chen JH; Wu TW
Thorac Cancer; 2023 Oct; 14(30):3012-3019. PubMed ID: 37667421
[TBL] [Abstract][Full Text] [Related]
32. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y
Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597
[TBL] [Abstract][Full Text] [Related]
33. Immune effects of CDK4/6 inhibitors in patients with HR
Scirocchi F; Scagnoli S; Botticelli A; Di Filippo A; Napoletano C; Zizzari IG; Strigari L; Tomao S; Cortesi E; Rughetti A; Marchetti P; Nuti M
EBioMedicine; 2022 May; 79():104010. PubMed ID: 35477069
[TBL] [Abstract][Full Text] [Related]
34. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
36. Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use.
Endo Y; Yoshimura A; Sawaki M; Hattori M; Kotani H; Kataoka A; Horisawa N; Ozaki Y; Nozawa K; Takatsuka D; Isogai A; Iwata H
J Breast Cancer; 2022 Aug; 25(4):296-306. PubMed ID: 36031754
[TBL] [Abstract][Full Text] [Related]
37. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
[TBL] [Abstract][Full Text] [Related]
38. Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer.
Franks J; Caston NE; Elkhanany A; Gerke T; Azuero A; Rocque GB
Breast Cancer Res Treat; 2023 Feb; 197(3):673-681. PubMed ID: 36539670
[TBL] [Abstract][Full Text] [Related]
39. CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients.
Crucitta S; Ruglioni M; Lorenzini G; Bargagna I; Luculli GI; Albanese I; Bilancio D; Patanè F; Fontana A; Danesi R; Del Re M
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831647
[TBL] [Abstract][Full Text] [Related]
40. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
